retatrutide phase 2 study results Perceived benefits of treatment for obesity with retatrutide: A qualitative of patients in a clinical trial Retatrutide just delivered the first

(2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

While data from a RCT controls for many of the potential confounding factors, using data from non-primary endpoints requires caveats

21 Remarkably, even in HF-free patients with morbid obesity, cardiac abnormalities can be seen that are consistent with left ventricular (LV) remodelling and dysfunction, including greater LV mass, LV diastolic dysfunction and elevated LV filling pressure

In other malignancies, including pulmonary and cutaneous neoplasms, no significant elevation in risk has been documented, with emerging evidence indicating potential protective properties